Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
Okay. A couple problems here. This study reviewed several statin drugs to determine which one lowered lipids better in patients with metabolic syndrome. You know metabolic syndrome the condition where high INSULIN levels increase lipids.
So here’s my analogy: Your house is on fire and the smoke detector is going off. We take a baseball bat, hammer and the wrong end of a screwdriver and beat on the smoke detector to see which one breaks the detector into the smallest pieces. Forget the fire–that’s not important.
And, just to be consistent with this study for my analogy, Astra Zeneca, the manufacturer of the hammer (which was found to be the most effective), paid for the study. Suspicious? And does anyone wonder why they didn’t check corresponding insulin levels?
